Home

Lipizzaner LLC

CIK 1783932 · last filed 2020-06-10

Lipizzaner LLC is a corporate insider who has filed 3 SEC Form 4 insider transactions across 1 company since 2020. The most recent filing shows the insider bought $19.7K of NBSE on Jun 10, 2020. Across all open-market trades the lifetime net is +$159.9K, making them a net buyer over the disclosed history. The firm reports its address in Wilmington, DE. 3 SEC filings were submitted jointly with Dietrich A Stephan.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$0

Companies

1

Total Filings

3

Lifetime Open-Market Net

$159.9K

Filer Profile

Reported Address
1209 ORANGE STREET
WILMINGTON, DE 19801
Phone
(650) 490-0166
Related Filers
Dietrich A Stephan — 3 joint filings, latest 2020-06-10
GEEX Sponsor, LLC — same reported address
GS Advisors VI, L.L.C. — same reported address
GS Capital Partners VI Fund, L.P. — same reported address
GS Capital Partners VI Offshore Fund, L.P. — same reported address
GSCP VI Advisors, L.L.C. — same reported address
GSCP VI Offshore Advisors, L.L.C. — same reported address
Innoviva Strategic Opportunities LLC — same reported address
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
NeuBase Therapeutics, Inc. (NBSE) Delisted 10%+ Owner 128,008 $0.38 $48.4K $159.9K 3 2020-06-10

Recent Filings

3 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2020-06-10 NeuBase Therapeutics, Inc. (NBSE) Delisted Buy (P) +2,550 $19.7K EDGAR
2020-05-26 NeuBase Therapeutics, Inc. (NBSE) Delisted Buy (P) +2,500 $20.2K EDGAR
2020-05-04 NeuBase Therapeutics, Inc. (NBSE) Delisted Buy (P) +20,000 $120.0K EDGAR
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.